TABLE 1

ROI Analysis

RegionPlacebo NGMEndotoxin NGMMean % differenceF1,40F1,88F1,56Uncorrected PCorrected P
Primary
 Amygdala0.72 ± 0.070.71 ± 0.07−0.5 ± 110.10.791
 Cingulate1.24 ± 0.071.21 ± 0.06−2.5 ± 3.25.80.0200.060
 Insula1.19 ± 0.031.23 ± 0.023.0 ± 3.6*6.30.0160.048*
Subregions
 Cingulate
 Anterior right1.23 ± 0.061.17 ± 0.07−4.5 ± 2.7*14.60.00020.0012*
 Anterior left1.23 ± 0.101.25 ± 0.072.0 ± 4.42.20.140.84
 Middle right1.30 ± 0.071.26 ± 0.08−3.4 ± 6.33.40.070.42
 Middle left1.23 ± 0.121.20 ± 0.08−2.3 ± 5.31.70.201
 Posterior right1.25 ± 0.131.19 ± 0.17−4.3 ± 111.2.271
 Posterior left1.01 ± 0.140.99 ± 0.22−2.8 ± 180.30.601
Insula
 Anterior right1.24 ± 0.081.30 ± 0.065.4 ± 9.15.70.02040.082
 Anterior left1.26 ± 0.051.29 ± 0.052.8 ± 4.31.70.1980.79
 Posterior right1.08 ± 0.081.12 ± 0.074.2 ± 6.52.40.1240.50
 Posterior left1.09 ± 0.081.07 ± 0.10−1.9 ± 6.30.70.4181
  • * Differences were considered significant at corrected P < 0.05 level.

  • Mean values (±SD) for NGM for each region and both conditions are shown. Mean percentage difference was mean of each individual subject's percentage difference between placebo and endotoxin.